NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: It promotes cell proliferation and survival, induces resistance to chemotherapy and mediates invasion and transformation.57 NF-κB activation was found to be involved in the occurrence of CML.56,58,59 Furthermore, NF-κB inhibitors have inhibitory effects on CML, and induces death of CML cells with the mutation of T315I Bcr-Abl,54,60 indicating that targeting NF-κB may be a valid avenue for the treatment of CML.